Abstract
Objectives: CFTR modulator therapy with Orkambi® (lumacaftor/ivacaftor) reduces the rate of decline of FEV1 in people with cystic fibrosis (PwCF) homozygous for the F508del mutation. However, the effect of Orkambi® on the composition and structure of the CF airway microbiota remains unclear. In this study, we determined the effect of therapy with Orkambi® on lung microbiota composition.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
